Cheaper copy of herceptin tested for stomach cancer – small study shows promise

NCT ID NCT04181333

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study by Pfizer tested a biosimilar (a near-copy) of trastuzumab in 8 people with advanced or recurrent HER2-positive gastric cancer that could not be removed by surgery. The goal was to check safety and how well the drug worked in real-world use. Participants received the biosimilar alongside other anti-cancer drugs, and doctors tracked side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab biosimilar (a copy of Herceptin)
What this could lead to: If this biosimilar works as well as the original drug, it could offer a more affordable treatment option for HER2-positive gastric cancer.
What could go wrong: This was a very small study (8 people) with no comparison group. Results may not apply to all patients, and biosimilars can have subtle differences in safety or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER

Contacts and locations

Locations

Pfizer

Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.